MBP and myeloid sarcoma: Having previously reported modeling of MS immunology and pathology in an HLA-DR15 and TCR transgenic model utilizing the same myelin basic protein (MBP) specific TCR as used by Birnbaum et al. [9], we, here, took the opportunity to investigate whether ‘environmental’ peptides implicated by the structural algorithm could indeed act by cross-reactivity to induce disease.